Blood:单细胞测序揭示驱动HSC体外生成的转录因子和分子通路

2020-07-14 MedSci原创 MedSci原创

一直以来,造血干细胞体外扩增都是一个难以克服的挑战,Fidanza等通过单细胞测序发现了参与HSC体外生成的转录因子和分子通路,是否有助于解决HSC体外难以有效扩增的困境?

造血干细胞和祖细胞(HSPC)在胚胎发育过程中的不同解剖部位通过不同的波来发育。人多能干细胞(hPSC)的体外分化能够重现其中的部分过程,但是,事实证明很难产生功能性造血干细胞(HSC)。

为了解析hPSC在体外产生HSPC的动力学和异质性,研究人员利用单细胞RNA测序(scRNAseq)与单细胞蛋白质表达分析相结合来进行研究。

生物信息学分析和功能验证确定了幼稚祖细胞和类红细胞,以及巨核细胞和白细胞定型祖细胞的转录组,明确CD44、CD326、ICAM2/CD9和CD18分别是这些祖细胞的标志物。

采用根据人胎儿肝脏的scRNAseq建立的人工神经网络(ANN),研究人员可鉴定出多种hPSCs衍生的HPSC表型,包括一小类被分类为HSCs的表型。

这种瞬时HSC样细胞群随着分化的进展而减少,最后在基于CD43表达筛选的细胞的数据集中完全消失。通过将体外产生的HSC样细胞的单细胞转录组与胎儿肝脏内产生的单细胞转录组进行对比,研究人员确定了将来可用于改善HSC体外生成的转录因子和分子途径。

原始出处:

Antonella Fidanza,et al. Single cell analyses and machine learning define hematopoietic progenitor and HSC-like cells derived from human PSCs. Blood. July 2,2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1658614, encodeId=ed66165861441, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu Dec 03 02:28:29 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747399, encodeId=b8ef1e4739907, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Sep 06 12:28:29 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537497, encodeId=d400153e497f6, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu Jul 16 05:28:29 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802769, encodeId=7370802e6986, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jul 14 15:37:51 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-12-03 sjq035
  2. [GetPortalCommentsPageByObjectIdResponse(id=1658614, encodeId=ed66165861441, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu Dec 03 02:28:29 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747399, encodeId=b8ef1e4739907, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Sep 06 12:28:29 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537497, encodeId=d400153e497f6, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu Jul 16 05:28:29 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802769, encodeId=7370802e6986, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jul 14 15:37:51 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-09-06 mjldent
  3. [GetPortalCommentsPageByObjectIdResponse(id=1658614, encodeId=ed66165861441, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu Dec 03 02:28:29 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747399, encodeId=b8ef1e4739907, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Sep 06 12:28:29 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537497, encodeId=d400153e497f6, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu Jul 16 05:28:29 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802769, encodeId=7370802e6986, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jul 14 15:37:51 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1658614, encodeId=ed66165861441, content=<a href='/topic/show?id=4d06914052' target=_blank style='color:#2F92EE;'>#HSC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9140, encryptionId=4d06914052, topicName=HSC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4bd24890262, createdName=sjq035, createdTime=Thu Dec 03 02:28:29 CST 2020, time=2020-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747399, encodeId=b8ef1e4739907, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sun Sep 06 12:28:29 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537497, encodeId=d400153e497f6, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Thu Jul 16 05:28:29 CST 2020, time=2020-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=802769, encodeId=7370802e6986, content=非常好的研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43a21971117, createdName=njwbhuang, createdTime=Tue Jul 14 15:37:51 CST 2020, time=2020-07-14, status=1, ipAttribution=)]
    2020-07-14 njwbhuang

    非常好的研究

    0

相关资讯

一波新的CRISPR工具浮出水面

2017年3月28日/生物谷BIOON/---当你读到这篇文章时,又一波CRISPR工具将会浮出水面。它们将需要接受测试和优化。不过,如果你询问开发者你在开展概念验证研究时是否应当试用它们时,你将仅获得鼓励。毕竟,迄今为止它们还不能从Addgene公司获得,但是将会很快上市了。 最新发布的一系列CRISPR工具包括新的谱系追踪方法,该方法能够提供一种窗口来研究发育的最早阶段。如

Nat Commun:单细胞测序揭示心肌细胞成熟机制

心肌细胞(CMs)是一种不同于心脏其他类型细胞的终末分化细胞,其不具备修复疾病或其他因素引起的心肌损伤的增殖能力。因此,重塑受损的心肌细胞仍是治疗如心肌梗死在内的心脏损伤性疾病的主要挑战。